The FDA approved the kinase inhibitor capmatinib for lung cancers harboring a certain mutation in the protein MET. The U.S. Food and Drug Administration (FDA) has granted full approval to capmatinib (Tabrecta) for the...
The FDA approved a HER2-targeted therapy for the treatment of breast tumors with low HER2 expression. The U.S. Food and Drug Administration (FDA) has approved fam-trastuzumab deruxtecan-nxki (Enhertu) for the treatment of adult patients...
The FDA approved darolutamide for the treatment of metastatic prostate cancer that is sensitive to hormone-blocking treatment. The U.S. Food and Drug Administration (FDA) has approved darolutamide (Nubeqa), in combination with the chemotherapy docetaxel,...
The FDA approved a kinase inhibitor for the treatment of inflammatory myofibroblastic tumors in children and adults. The U.S. Food and Drug Administration has approved crizotinib (Xalkori) for the treatment of certain patients 1...
The CAR T-cell therapy lisocabtagene maraleucel was approved for the second-line treatment of certain patients with large B-cell lymphoma. The U.S. Food and Drug Administration (FDA) has approved lisocabtagene maraleucel (Breyanzi) for the second-line...
Ibrutinib, a small molecule inhibitor of B-cell proliferation, was approved for pediatric patients with chronic graft-versus-host disease. The U.S. Food and Drug Administration (FDA) has approved ibrutinib (Imbruvica) for pediatric patients 1 year of...
The FDA approved a combination of two kinase inhibitors for the treatment of solid tumors bearing the BRAF V600E mutation. The U.S. Food and Drug Administration (FDA) has granted accelerated approval to the kinase...
The FDA has approved an immunotherapy to be used in combination with another immunotherapy or chemotherapy for the treatment of esophageal squamous cell carcinoma. The U.S. Food and Drug Administration (FDA) has approved the...
The FDA granted accelerated approval to a CAR T-cell therapy for certain adult patients with follicular lymphoma. The U.S. Food and Drug Administration (FDA) granted accelerated approval to tisagenlecleucel (Kymriah) for certain adult patients...
The FDA approved a new regimen that includes a molecularly targeted therapeutic for some older leukemia patients not eligible for intensive chemotherapy. The U.S. Food and Drug Administration (FDA) has approved ivosidenib (Tibsovo) in...
AACR Fellow Lewis C. Cantley, PhD, leads a national effort targeting triple-negative breast cancer and ovarian cancer with a novel drug combination.
Learn More